Targeting the Choroid Plexus-CSF-Brain Nexus Using Peptides Identified by Phage Display

  • Andrew Baird
  • Brian P. Eliceiri
  • Ana Maria Gonzalez
  • Conrad E. Johanson
  • Wendy Leadbeater
  • Edward G. Stopa
Part of the Methods in Molecular Biology book series (MIMB, volume 686)


Drug delivery to the central nervous system requires the use of specific portals to enable drug entry into the brain and, as such, there is a growing need to identify processes that can enable drug transfer across both blood-brain and blood–cerebrospinal fluid barriers. Phage display is a powerful combinatorial technique that identifies specific peptides that can confer new activities to inactive particles. Identification of these peptides is directly dependent on the specific screening strategies used for their selection and retrieval. This chapter describes three selection strategies, which can be used to identify peptides that target the choroid plexus (CP) directly or for drug translocation across the CP and into cerebrospinal fluid.

Key words

Blood-brain barrier Choroid plexus Choroid epithelial cells CNS targeting Library screening Combinatorial biology Blood-CSF barrier Drug translocation Ex vivo biopanning Ligand internalization Phage display Screening 



This work was supported in part by the National Institutes of Health (USA) and the Biochemistry and Biotechnology Research Council (UK). The authors would like to thank Drs. Paul Kassner and David Larocca who first engineered the initial EGF-displayed phage that helped establish the feasibility of CP targeting, Dr. Michael Burg who helped identify CP-targeting peptides in peptide libraries, and Ms. Emelie Amburn and Dr. Karen Sims who assisted in their characterization.


  1. 1.
    Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317CrossRefPubMedGoogle Scholar
  2. 2.
    Barbas CF (2001) Phage display: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor LaboratoryGoogle Scholar
  3. 3.
    Pasqualini R, Arap W, McDonald DM (2002) Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 8:563–571CrossRefPubMedGoogle Scholar
  4. 4.
    Larocca D, Baird A (2001) Receptor-mediated gene transfer by phage-display vectors: applications in functional genomics and gene therapy. Drug Discov Today 6:793–801CrossRefPubMedGoogle Scholar
  5. 5.
    Larocca D, Burg MA, Jensen-Pergakes K, Ravey EP, Gonzalez AM, Baird A (2002) Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol 3:45–57CrossRefPubMedGoogle Scholar
  6. 6.
    Larocca D, Jensen-Pergakes K, Burg MA, Baird A (2001) Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther 3:476–484CrossRefPubMedGoogle Scholar
  7. 7.
    Larocca D, Jensen-Pergakes K, Burg MA, Baird A (2002) Gene transfer using targeted filamentous bacteriophage. Methods Mol Biol 185:393–401PubMedGoogle Scholar
  8. 8.
    Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A (1999) Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. Faseb J 13:727–734PubMedGoogle Scholar
  9. 9.
    Larocca D, Witte A, Johnson W, Pierce GF, Baird A (1998) Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther 9:2393–2399CrossRefPubMedGoogle Scholar
  10. 10.
    Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, Williamson R, Coutelle C (1994) Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem 269:12468–12474PubMedGoogle Scholar
  11. 11.
    Ivanenkov VV, Menon AG (2000) Peptide-mediated transcytosis of phage display vectors in MDCK cells. Biochem Biophys Res Commun 276:251–257CrossRefPubMedGoogle Scholar
  12. 12.
    Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188–3192CrossRefPubMedGoogle Scholar
  13. 13.
    Muruganandam A, Tanha J, Narang S, Stanimirovic D (2002) Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. Faseb J 16:240–242PubMedGoogle Scholar
  14. 14.
    Pasqualini R (1999) Vascular targeting with phage peptide libraries. Q J Nucl Med 43:159–162PubMedGoogle Scholar
  15. 15.
    Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366CrossRefPubMedGoogle Scholar
  16. 16.
    Pasqualini R, Ruoslahti E (1996) Searching for a molecular address in the brain. Mol Psychiatry 1:421–422PubMedGoogle Scholar
  17. 17.
    Pasqualini R, Ruoslahti E (1996) Tissue targeting with phage peptide libraries. Mol Psychiatry 1:423PubMedGoogle Scholar
  18. 18.
    Petrenko VA, Smith GP (2000) Phage from landscape libraries as substitute antibodies. Protein Eng 13:589–592CrossRefPubMedGoogle Scholar
  19. 19.
    Petrenko VA, Smith GP, Gong X, Quinn T (1996) A library of organic landscapes on filamentous phage. Protein Eng 9:797–801CrossRefPubMedGoogle Scholar
  20. 20.
    Poul MA, Marks JD (1999) Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 288:203–211CrossRefPubMedGoogle Scholar
  21. 21.
    Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437CrossRefPubMedGoogle Scholar
  22. 22.
    Sokoloff AV, Bock I, Zhang G, Sebestyen MG, Wolff JA (2000) The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Mol Ther 2:131–139CrossRefPubMedGoogle Scholar
  23. 23.
    Yip YL, Hawkins NJ, Smith G, Ward RL (1999) Biodistribution of filamentous phage-Fab in nude mice. J Immunol Methods 225:171–178CrossRefPubMedGoogle Scholar
  24. 24.
    Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774CrossRefPubMedGoogle Scholar
  25. 25.
    Koivunen E, Restel BH, Rajotte D, Lahdenranta J, Hagedorn M, Arap W, Pasqualini R (1999) Integrin-binding peptides derived from phage display libraries. Methods Mol Biol 129:3–17PubMedGoogle Scholar
  26. 26.
    Trepel M, Arap W, Pasqualini R (2000) Exploring vascular heterogeneity for gene therapy targeting. Gene Ther 7:2059–2060CrossRefPubMedGoogle Scholar
  27. 27.
    Trepel M, Grifman M, Weitzman MD, Pasqualini R (2000) Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther 11:1971–1981CrossRefPubMedGoogle Scholar
  28. 28.
    Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D (2002) Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 62:977–981PubMedGoogle Scholar
  29. 29.
    Burg M, Ravey EP, Gonzales M, Amburn E, Faix PH, Baird A, Larocca D (2004) Selection of internalizing ligand-display phage using rolling circle amplification for phage recovery. DNA Cell Biol 23:457–462CrossRefPubMedGoogle Scholar
  30. 30.
    Kassner PD, Burg MA, Baird A, Larocca D (1999) Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells. Biochem Biophys Res Commun 264:921–928CrossRefPubMedGoogle Scholar
  31. 31.
    Chodobski A, Szmydynger-Chodobska J (2001) Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech 52:65–82CrossRefPubMedGoogle Scholar
  32. 32.
    Emerich DF, Vasconcellos AV, Elliott RB, Skinner SJ, Borlongan CV (2004) The choroid plexus: function, pathology and therapeutic potential of its transplantation. Expert Opin Biol Ther 4:1191–1201CrossRefPubMedGoogle Scholar
  33. 33.
    Ghersi-Egea JF, Strazielle N (2002) Choroid plexus transporters for drugs and other xenobiotics. J Drug Target 10:353–357CrossRefPubMedGoogle Scholar
  34. 34.
    Johanson CE, Duncan JA, Stopa EG, Baird A (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011–1037CrossRefPubMedGoogle Scholar
  35. 35.
    Silverberg GD, Huhn S, Jaffe RA, Chang SD, Saul T, Heit G, Von Essen A, Rubenstein E (2002) Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus. J Neurosurg 97:1271–1275CrossRefPubMedGoogle Scholar
  36. 36.
    Spector R, Johanson C (2006) Micronutrient and urate transport in choroid plexus and kidney: implications for drug therapy. Pharm Res 23:2515–2524CrossRefPubMedGoogle Scholar
  37. 37.
    Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I (2005) Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25:10884–10893CrossRefPubMedGoogle Scholar
  38. 38.
    Hakvoort A, Haselbach M, Galla HJ (1998) Active transport properties of porcine choroid plexus cells in culture. Brain Res 795:247–256CrossRefPubMedGoogle Scholar
  39. 39.
    Johanson CE, Gonzalez AM, Stopa EG (2001) Water-imbalance-induced expression of FGF-2 in fluid-regulatory centers: choroid plexus and neurohypophysis. Eur J Pediatr Surg 11 Suppl 1:S37–38PubMedGoogle Scholar
  40. 40.
    Liao CW, Fan CK, Kao TC, Ji DD, Su KE, Lin YH, Cho WL (2008) Brain injury-associated biomarkers of TGF-beta1, S100B, GFAP, NF-L, tTG, AbetaPP, and tau were concomitantly enhanced and the UPS was impaired during acute brain injury caused by Toxocara canis in mice. BMC Infect Dis 8:84CrossRefPubMedGoogle Scholar
  41. 41.
    Parandoosh Z, Johanson CE (1982) Ontogeny of blood-brain barrier permeability to, and cerebrospinal fluid sink action on, [14C] urea. Am J Physiol 243:R400–407PubMedGoogle Scholar
  42. 42.
    Schreiber G (2002) The evolution of transthyretin synthesis in the choroid plexus. Clin Chem Lab Med 40:1200–1210CrossRefPubMedGoogle Scholar
  43. 43.
    Borlongan CV, Thanos CG, Skinner SJ, Geaney M, Emerich DF (2008) Transplants of encapsulated rat choroid plexus cells exert neuroprotection in a rodent model of Huntington’s disease. Cell Transplant 16:987–992CrossRefPubMedGoogle Scholar
  44. 44.
    Emerich DF, Skinner SJ, Borlongan CV, Thanos CG (2005) A role of the choroid plexus in transplantation therapy. Cell Transplant 14:715–725CrossRefPubMedGoogle Scholar
  45. 45.
    Johanson CE, Szmydynger-Chodobska J, Chodobski A, Baird A, McMillan P, Stopa EG (1999) Altered formation and bulk absorption of cerebrospinal fluid in FGF-2-induced hydrocephalus. Am J Physiol 277:R263–271PubMedGoogle Scholar
  46. 46.
    Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird A (1992) Enhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Res 587:216–225CrossRefPubMedGoogle Scholar
  47. 47.
    Stopa EG, Berzin TM, Kim S, Song P, Kuo-LeBlanc V, Rodriguez-Wolf M, Baird A, Johanson CE (2001) Human choroid plexus growth factors: What are the implications for CSF dynamics in Alzheimer’s disease? Exp Neurol 167:40–47CrossRefPubMedGoogle Scholar
  48. 48.
    Strazielle N, Ghersi-Egea JF (1999) Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci 19:6275–6289PubMedGoogle Scholar
  49. 49.
    Vercellino M, Votta B, Condello C, Piacentino C, Romagnolo A, Merola A, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P (2008) Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J Neuroimmunol 199:133–141CrossRefPubMedGoogle Scholar
  50. 50.
    Saggio I, Gloaguen I, Laufer R (1995) Functional phage display of ciliary neurotrophic factor. Gene 152:35–39CrossRefPubMedGoogle Scholar
  51. 51.
    Buchli PJ, Wu Z, Ciardelli TL (1997) The functional display of interleukin-2 on filamentous phage. Arch Biochem Biophys 339:79–84CrossRefPubMedGoogle Scholar
  52. 52.
    Hosoya K, Hori S, Ohtsuki S, Terasaki T (2004) A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Adv Drug Deliv Rev 56:1875–1885CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Andrew Baird
    • 1
  • Brian P. Eliceiri
    • 1
  • Ana Maria Gonzalez
    • 2
  • Conrad E. Johanson
    • 3
  • Wendy Leadbeater
    • 2
  • Edward G. Stopa
    • 4
  1. 1.Department of Surgery, Division of Trauma, Burns and Critical CareUniversity of California San DiegoSan DiegoUSA
  2. 2.Molecular Neuroscience Group, School of MedicineUniversity of BirminghamBirminghamUK
  3. 3.Department of Clinical NeuroscienceAlpert Medical School at Brown UniversityProvidenceUSA
  4. 4.Department of PathologyAlpert Medical School at Brown UniversityProvidenceUSA

Personalised recommendations